Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial
Authors
Anne Marie Morse (ORCID: https://orcid.org/0000-0003-4494-0195)
Lois E. Krahn
John W. Winkelman (ORCID: https://orcid.org/0000-0003-1673-5418)
Jennifer Gudeman (ORCID: https://orcid.org/0000-0002-7375-5020)
Asim Roy (ORCID: https://orcid.org/0000-0002-8530-0242)
Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial
Anne Marie Morse, Lois E. Krahn, John W. Winkelman, Jennifer Gudeman et al.
Citations
2 citations
Journal
CNS Drugs
Topics
Sleep and Wakefulness Research
Field-Weighted Citation Impact (FWCI)
2.86
article
Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial
Anne Marie Morse, Lois E. Krahn, John W. Winkelman, Jennifer Gudeman, Asim Roy
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
CNS DrugsVol. 39(S1)
Institutions
Geisinger Medical Center (US), University of Chester (GB), Massachusetts General Hospital (US), Sleep Management Institute (US), Mayo Clinic Hospital (US), Geisinger Commonwealth School of Medicine (US)
Funders
Neuroscience Research Australia, Harmony Biosciences